Regulation of adipokine secretion by n-3 fatty acids

Proceedings of the Nutrition Society

Volumn 69, Issue 3, 2010, Pages 324-332

  Moreno Aliaga, María J ^a   Lorente Cebrián, Silvia ^a   Martínez, J Alfredo ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Adiponectin; Inflammation; Leptin; n 3 fatty acids; Obesity; Visfatin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; GLUCOSE TRANSPORTER 4; ICOSANOID; INTERLEUKIN 12; INTERLEUKIN 6; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FATTY ACID OXIDATION; GENE EXPRESSION; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; METABOLIC REGULATION; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; TISSUE METABOLISM; VASCULITIS; WHITE ADIPOSE TISSUE;

ADIPOKINES; ADIPOSE TISSUE, WHITE; ANIMALS; FATTY ACIDS, OMEGA-3; HUMANS; INSULIN RESISTANCE; OBESITY;

MUS; RODENTIA;

EID: 77957361839     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665110001801     Document Type: Conference Paper

References (120)

1. Sethi JK & Vidal-Puig AJ (2007) Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res 48, 1253-1262.
2. Gurevich-Panigrahi T, Panigrahi S, Wiechec E et al. (2009) Obesity: pathophysiology and clinical management. Curr Med Chem 16, 506-521.
3. Marti A, Marcos A & Martinez JA (2001) Obesity and immune function relationships. Obes Rev 2, 131-140.
4. Scherer PE (2006) Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 55, 1537-1545.
5. Trayhurn P (2005) Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand 184, 285-293.
6. Havel PJ (2004) Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 53, Suppl. 1, S143-S151.
7. Boucher J, Masri B, Daviaud D et al. (2005) Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 146, 1764-1771.
8. de Souza Batista CM, Yang RZ, Lee MJ et al. (2007) Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56, 1655-1661.
9. Trayhurn P & Wood IS (2005) Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 33, 1078-1081.
10. Das UN (2001) Is obesity an inflammatory condition? Nutrition 17, 953-966.
11. Jump DB & Clarke SD (1999) Regulation of gene expression by dietary fat. Annu Rev Nutr 19, 63-90.
12. Bray GA, Lovejoy JC, Smith SR et al. (2002) The influence of different fats and fatty acids on obesity, insulin resistance and inflammation. J Nutr 132, 2488-2491.
13. Kraegen EW, Clark PW, Jenkins AB et al. (1991) Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 40, 1397-1403.
14. Storlien LH, Kraegen EW, Chisholm DJ et al. (1987) Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 237, 885-888.
15. Ruzickova J, Rossmeisl M, Prazak T et al. (2004) Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids 39, 1177-1185.
16. Flachs P, Horakova O, Brauner P et al. (2005) Polyunsaturated fatty acids of marine origin upregulate mitochondrial biogenesis and induce beta-oxidation in white fat. Diabetologia 48, 2365-2375.
17. Pérez-Matute P, Pérez-Echarri N, Martínez JA et al. (2007) Eicosapentaenoic acid actions on adiposity and insulin resistance in control and high-fat-fed rats: role of apoptosis, adiponectin and tumour necrosis factor-alpha. Br J Nutr 97, 389-398.
18. Perez-Echarri N, Perez-Matute P, Marcos-Gomez B et al. (2009) Effects of eicosapentaenoic acid ethyl ester on visfatin and apelin in lean and overweight (cafeteria diet-fed) rats. Br J Nutr 101, 1059-1067.
19. Perez-Echarri N, Perez-Matute P, Marcos-Gomez B et al. (2009) Down-regulation in muscle and liver lipogenic genes: EPA ethyl ester treatment in lean and overweight (high-fat-fed) rats. J Nutr Biochem 20, 705-714.
20. Kunesova M, Braunerova R, Hlavaty P et al. (2006) The influence of n-3 polyunsaturated fatty acids and very low calorie diet during a short-term weight reducing regimen on weight loss and serum fatty acid composition in severely obese women. Physiol Res 55, 63-72.
21. Takahashi M, Tsuboyama-Kasaoka N, Nakatani T et al. (2002) Fish oil feeding alters liver gene expressions to defend against PPARalpha activation and ROS production. Am J Physiol Gastrointest Liver Physiol 282, G338-348.
22. Kim HJ, Takahashi M & Ezaki O (1999) Fish oil feeding decreases mature sterol regulatory element-binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse liver. A possible mechanism for down-regulation of lipogenic enzyme mRNAs. J Biol Chem 274, 25892-25898.
23. Delarue J, LeFoll C, Corporeau C et al. (2004) N-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity? Reprod Nutr Dev 44, 289-299.
24. Peyron-Caso E, Fluteau-Nadler S, Kabir M et al. (2002) Regulation of glucose transport and transporter 4 (GLUT-4) in muscle and adipocytes of sucrose-fed rats: effects of N-3 poly-and monounsaturated fatty acids. Horm Metab Res 34, 360-366.
25. Ruggiero C, Lattanzio F, Lauretani F et al. (2009) Omega-3 polyunsaturated fatty acids and immune-mediated diseases: inflammatory bowel disease and rheumatoid arthritis. Curr Pharm Des 15, 4135-4148.
26. White PJ & Marette A (2006) Is omega-3 key to unlocking inflammation in obesity? Diabetologia 49, 1999-2001.
27. Calder PC (2006) n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83, 1505S-1519S.
28. Serhan CN, Hong S, Gronert K et al. (2002) Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196, 1025-1037.
29. Serhan CN, Chiang N & Van Dyke TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8, 349-361.
30. Gonzalez-Periz A, Horrillo R, Ferre N et al. (2009) Obesityinduced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 23, 1946-1957.
31. Flachs P, Rossmeisl M, Bryhn M et al. (2009) Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin Sci (Lond) 116, 1-16.
32. Todoric J, Loffler M, Huber J et al. (2006) Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 49, 2109-2119.
33. Pérez-Echarri N, Pérez-Matute P, Marcos-Gómez B et al. (2008) Differential inflammatory status in rats susceptible or resistant to diet-induced obesity: effects of EPA ethyl ester treatment. Eur J Nutr 47, 380-386.
34. Pérez-Matute P, Marti A, Martínez JA et al. (2005) Eicosapentaenoic fatty acid increases leptin secretion from primary cultured rat adipocytes: role of glucose metabolism. Am J Physiol Regul Integr Comp Physiol 288, R1682-1688.
35. Itoh M, Suganami T, Satoh N et al. (2007) Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 27, 1918-1925.
36. Marti A, Berraondo B & Martinez JA (1999) Leptin: physiological actions. J Physiol Biochem 55, 43-49.
37. Zhang Y, Proenca R, Maffei M et al. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432.
38. Montague CT, Farooqi IS, Whitehead JP et al. (1997) Congenital leptin deficiency is associated with severe early-onset obesity in human subjects. Nature 387, 903-908.
39. Havel PJ, Kasim-Karakas S, Mueller W et al. (1996) Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 81, 4406-4413.
40. Ahren B, Mansson S, Gingerich RL et al. (1997) Regulation of plasma leptin in mice: influence of age, high-fat diet, and fasting. Am J Physiol 273, R113-120.
41. Lee MJ & Fried SK (2009) Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion. Am J Physiol Endocrinol Metab 296, E1230-E1238.
42. Keim NL, Stern JS & Havel PJ (1998) Relation between circulating leptin concentrations and appetite during a prolonged, moderate energy deficit in women. Am J Clin Nutr 68, 794-801.
43. Rosenbaum M, Murphy EM, Heymsfield SB et al. (2002) Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab 87, 2391-2394.
44. Caprio M, Fabbrini E, Isidori AM et al. (2001) Leptin in reproduction. Trends Endocrinol Metab 12, 65-72.
45. La Cava A & Matarese G (2004) The weight of leptin in immunity. Nat Rev Immunol 4, 371-379.
46. Farooqi IS, Matarese G, Lord GM et al. (2002) Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110, 1093-1103.
47. Sarraf P, Frederich RC, Turner EM et al. (1997) Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med 185, 171-175.
48. Matarese G, Leiter EH & La Cava A (2007) Leptin in autoimmunity: many questions, some answers. Tissue Antigens 70, 87-95.
49. Shen J, Sakaida I, Uchida K et al. (2005) Leptin enhances TNFalpha production via p38 and JNK MAPK in LPS-stimulated Kupffer cells. Life Sci 77, 1502-1515.
50. Santos-Alvarez J, Goberna R & Sanchez-Margalet V (1999) Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol 194, 6-11.
51. Zarkesh-Esfahani H, Pockley AG, Wu Z et al. (2004) Leptin indirectly activates human neutrophils via induction of TNFalpha. J Immunol 172, 1809-1814.
52. Zhao Y, Sun R, You L et al. (2003) Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines. Biochem Biophys Res Commun 300, 247-252.
53. Howard JK, Lord GM, Matarese G et al. (1999) Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J Clin Invest 104, 1051-1059.
54. Tilg H & Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6, 772-783.
55. Murata M, Kaji H, Takahashi Y et al. (2000) Stimulation by eicosapentaenoic acids of leptin mRNA expression and its secretion in mouse 3T3-L1 adipocytes in vitro. Biochem Biophys Res Commun 270, 343-348.
56. Mueller WM, Gregoire FM, Stanhope KL et al. (1998) Evidence that glucose metabolism regulates leptin secretion from cultured rat adipocytes. Endocrinology 139, 551-558.
57. Moreno-Aliaga MJ, Swarbrick MM, Lorente-Cebrian S et al. (2007) Sp1-mediated transcription is involved in the induction of leptin by insulin-stimulated glucose metabolism. J Mol Endocrinol 38, 537-546.
58. Moreno-Aliaga MJ, Stanhope KL & Havel PJ (2001) Transcriptional regulation of the leptin promoter by insulinstimulated glucose metabolism in 3t3-L1 adipocytes. Biochem Biophys Res Commun 283, 544-548.
59. Cammisotto PG, Gelinas Y, Deshaies Y et al. (2003) Regulation of leptin secretion from white adipocytes by free fatty acids. Am J Physiol Endocrinol Metab 285, E521-E526.
60. Raclot T, Groscolas R, Langin D et al. (1997) Site-specific regulation of gene expression by n-3 polyunsaturated fatty acids in rat white adipose tissues. J Lipid Res 38, 1963-1972.
61. Reseland JE, Haugen F, Hollung K et al. (2001) Reduction of leptin gene expression by dietary polyunsaturated fatty acids. J Lipid Res 42, 743-750.
62. Peyron-Caso E, Taverna M, Guerre-Millo M et al. (2002) Dietary (n-3) polyunsaturated fatty acids up-regulate plasma leptin in insulin-resistant rats. J Nutr 132, 2235-2240.
63. Rossi AS, Lombardo YB, Lacorte JM et al. (2005) Dietary fish oil positively regulates plasma leptin and adiponectin levels in sucrose-fed, insulin-resistant rats. Am J Physiol Regul Integr Comp Physiol 289, R486-R494.
64. Ramel A, Parra D, Martinez JA et al. (2009) Effects of seafood consumption and weight loss on fasting leptin and ghrelin concentrations in overweight and obese European young adults. Eur J Nutr 48, 107-114.
65. Pajvani UB, Hawkins M, Combs TP et al. (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279, 12152-12162.
66. Bruun JM, Lihn AS, Verdich C et al. (2003) Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in human subjects. Am J Physiol Endocrinol Metab 285, E527-533.
67. Qi Y, Takahashi N, Hileman SM et al. (2004) Adiponectin acts in the brain to decrease body weight. Nat Med 10, 524-529.
68. Yamauchi T, Kamon J, Waki H et al. (2001) The fatderived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7, 941-946.
69. Kumada M, Kihara S, Sumitsuji S et al. (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23, 85-89.
70. Kubota N, Terauchi Y, Yamauchi T et al. (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277, 25863-25866.
71. Maeda N, Shimomura I, Kishida K et al. (2002) Dietinduced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8, 731-737.
72. Combs TP, Pajvani UB, Berg AH et al. (2004) A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145, 367-383.
73. Combs TP, Wagner JA, Berger J et al. (2002) Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143, 998-1007.
74. Ouchi N, Kihara S, Arita Y et al. (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102, 1296-1301.
75. Yokota T, Oritani K, Takahashi I et al. (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96, 1723-1732.
76. Wolf AM, Wolf D, Rumpold H et al. (2004) Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 323, 630-635.
77. Fasshauer M, Kralisch S, Klier M et al. (2003) Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 301, 1045-1050.
78. Flachs P, Mohamed-Ali V, Horakova O et al. (2006) Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 49, 394-397.
79. Neschen S, Morino K, Rossbacher JC et al. (2006) Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes 55, 924-928.
80. Lorente-Cebrián S, Pérez-Matute P, Martínez JA et al. (2006) Effects of eicosapentaenoic acid (EPA) on adiponectin gene expression and secretion in primary cultured rat adipocytes. J Physiol Biochem 62, 61-69.
81. Long YC & Zierath JR (2006) AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 116, 1776-1783.
82. Fryer LG, Parbu-Patel A & Carling D (2002) The Antidiabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277, 25226-25232.
83. Lihn AS, Jessen N, Pedersen SB et al. (2004) AICAR stimulates adiponectin and inhibits cytokines in adipose tissue. Biochem Biophys Res Commun 316, 853-858.
84. Lorente-Cebrian S, Bustos M, Marti A et al. (2009) Eicosapentaenoic acid stimulates AMP-activated protein kinase and increases visfatin secretion in cultured murine adipocytes. Clin Sci (Lond) 117, 243-249.
85. Kopecky J, Rossmeisl M, Flachs P et al. (2009) n-3 PUFA: bioavailability and modulation of adipose tissue function. Proc Nutr Soc 68, 361-369.
86. Fukuhara A, Matsuda M, Nishizawa M et al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307, 426-430. (Pubitemid 40139988)
87. Samal B, Sun Y, Stearns G et al. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14, 1431-1437.
88. Tilg H & Moschen AR (2008) Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 114, 275-288.
89. Revollo JR, Grimm AA & Imai S (2007) The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 23, 164-170.
90. Luk T, Malam Z & Marshall JC (2008) Pre-B cell colonyenhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 83, 804-816.
91. Moschen AR, Kaser A, Enrich B et al. (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178, 1748-1758.
92. Li Y, Zhang Y, Dorweiler B et al. (2008) Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem 283, 34833-34843.
93. Romacho T, Azcutia V, Vazquez-Bella M et al. (2009) Extracellular PBEF/NAMPT/visfatin activates proinflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 52, 2455-2463.
94. Liu SW, Qiao SB, Yuan JS et al. (2009) Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in human subjects. Clin Endocrinol (Oxf) 71, 202-207.
95. Kralisch S, Klein J, Lossner U et al. (2005) Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 185, R1-8.
96. Kralisch S, Klein J, Lossner U et al. (2005) Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 289, E586-590.
97. Hector J, Schwarzloh B, Goehring J et al. (2007) TNFalpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 39, 250-255.
98. Kloting N & Kloting I (2005) Visfatin: gene expression in isolated adipocytes and sequence analysis in obese WOKW rats compared with lean control rats. Biochem Biophys Res Commun 332, 1070-1072.
99. Choi KC, Ryu OH, Lee KW et al. (2005) Effect of PPAR-alpha and-gamma agonist on the expression of visfatin, adiponectin, and TNFalpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 336, 747-753.
100. Choi KC, Lee SY, Yoo HJ et al. (2007) Effect of PPAR-delta agonist on the expression of visfatin, adiponectin, and resistin in rat adipose tissue and 3T3-L1 adipocytes. Biochem Biophys Res Commun 357, 62-67.
101. Filippatos TD, Derdemezis CS, Kiortsis DN et al. (2007) Increased plasma levels of visfatin/pre-B cell colonyenhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 30, 323-326.
102. Haider DG, Holzer G, Schaller G et al. (2006) The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr 43, 548-549.
103. Berndt J, Kloting N, Kralisch S et al. (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in human subjects. Diabetes 54, 2911-2916.
104. Hammarstedt A, Pihlajamaki J, Rotter Sopasakis V et al. (2006) Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 91, 1181-1184.
105. Wang P, van Greevenbroek MM, Bouwman FG et al. (2007) The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch 454, 971-976.
106. Pagano C, Pilon C, Olivieri M et al. (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in human subjects. J Clin Endocrinol Metab 91, 3165-3170.
107. Krzyzanowska K, Mittermayer F, Krugluger W et al. (2006) Increase in visfatin after weight loss induced by gastroplastic surgery. Obesity (Silver Spring) 14, 1886-1889.
108. Garcia-Fuentes E, Garcia-Almeida JM, Garcia-Arnes J et al. (2007) Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass. Obesity (Silver Spring) 15, 2391-2395.
109. Haider DG, Schindler K, Schaller G et al. (2006) Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91, 1578-1581.
110. Manco M, Fernandez-Real JM, Equitani F et al. (2007) Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab 92, 483-490.
111. Chen MP, Chung FM, Chang DM et al. (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91, 295-299.
112. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J et al. (2007) Serum concentration of visfatin in obese women. Metabolism 56, 1131-1134.
113. Fukuhara A, Matsuda M, Nishizawa M et al. (2007) Retraction. Science 318, 565.
114. Wen Y, Wang HW, Wu J et al. (2006) Effects of fatty acid regulation on visfatin gene expression in adipocytes. Chin Med J (Engl) 119, 1701-1708.
115. Haider DG, Mittermayer F, Schaller G et al. (2006) Free fatty acids normalize a rosiglitazone-induced visfatin release. Am J Physiol Endocrinol Metab 291, E885-890.
116. Lichtenstein AH, Appel LJ, Brands M et al. (2006) Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 114, 82-96.
117. European Food Safety Authority (2009) Scientific Opinion on the substantiation of health claims related to EPA, DHA, DPA and maintenance of normal blood pressure (ID 502), maintenance of normal HDL-cholesterol concentrations (ID 515), maintenance of normal (fasting) blood concentrations of triglycerides (ID 517), maintenance of normal LDL-cholesterol concentrations (ID 528, 698) and maintenance of joints (ID 503, 505, 507, 511, 518, 524, 526, 535, 537) pursuant to Article 13 (1) of Regulation (EC) No 1924/2006. EFSA J 7, 1263.
118. Fetterman JW Jr & Zdanowicz MM (2009) Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am J Health Syst Pharm 66, 1169-1179.
119. He K (2009) Fish, long-chain omega-3 polyunsaturated fatty acids and prevention of cardiovascular disease - eat fish or take fish oil supplement? Prog Cardiovasc Dis 52, 95-114.
120. Weber HS, Selimi D & Huber G (2006) Prevention of cardiovascular diseases and highly concentrated n-3 polyunsaturated fatty acids (PUFAs). Herz 31, Suppl. 3, 24-30.